Our findings highlight the immunoregulatory role of FOXM1 in cancer cells, suggesting the need for future investigations exploring FOXM1 as a prognostic biomarker, in addition to PD‐L1, for cancer immunotherapy. This evidence concerns the gene FOXM1 and cancer.